In vitro antifungal activity of DNA topoisomerase inhibitors

References

• Castón-Osorio JJ, Rivero A, Torre-Cisneros J. Epidemiology of invasive fungal infection. Int J Antimicrob Agents 2008; 32 (Suppl. 2): S103–109.
   Web of Science ®Google Scholar
• Denning DW. Echinocandin antifungal drugs. Lancet 2003; 362: 1142–1151.
   PubMed Web of Science ®Google Scholar
• Fostel JM, Montgomery DA, Shen LL. Characterization of DNA topoisomerase I from Candida albicans as a target for drug discovery. Antimicrob Agents Chemother 1992; 36: 2131–2138.
   PubMedGoogle Scholar
• Shen LL, Baranowski J, Fostel J, Montgomery DA, Lartey PA. DNA topoisomerases from pathogenic fungi: targets for the discovery of antifungal drugs. Antimicrob Agents Chemother 1992; 36: 2778–2784.
   PubMed Web of Science ®Google Scholar
• Taylor A, Giles K, Sarthy AV, McGonigal T, Fostel J. Identification of the gene encoding DNA topoisomerase I from Candida albicans. FEMS Microbiol Lett 1996; 138: 113–121.
   PubMedGoogle Scholar
• Jiang W, Gerhold D, Kmiec EB, . The topoisomerase I gene from Candida albicans. Microbiology 1997; 143: 377–386.
   PubMedGoogle Scholar
• Keller BA, Patel S, Fisher LM. Molecular cloning and expression of the Candida albicans TOP2 gene allows study of fungal DNA topoisomerase II inhibitors in yeast. Biochem J 1997; 324: 329–339.
   PubMed Web of Science ®Google Scholar
• Van Dross RT, Rao KV, Eisenberg E, Sanders MM. Cloning and characterization of the Aspergillus nidulans DNA topoisomerase I gene. Gene 1997; 203: 169–174.
   PubMedGoogle Scholar
• Del Poeta M, Toffaletti DL, Rude TH, . Topoisomerase I is essential in Cryptococcus neoformans: role in pathobiology and as an antifungal target. Genetics 1999; 152: 167–178.
   PubMed Web of Science ®Google Scholar
• Kim KH, Akashi T, Mizuguchi I, Kikuchi A. Cloning and characterization of the gene encoding Aspergillus nidulans DNA topoisomerase II. Gene 1999; 236: 293–301.
   PubMedGoogle Scholar
• Corbett KD, Berger JM. Structure, molecular mechanisms, and evolutionary relationships in DNA topoisomerases. Annu Rev Biophys Biomol Struct 2004; 33: 95–118.
   PubMedGoogle Scholar
• Kwok SC, Schelenz S, Wang X, Steverding D. In vitro effect of DNA topoisomerase inhibitors on Candida albicans. Med Mycol 2010; 48: 155–160.
   PubMed Web of Science ®Google Scholar
• Huber W, Koella JC. A comparison of three methods of estimating EC50 in studies of drug resistance of malaria parasites. Acta Trop 1993; 55: 257–261.
   PubMed Web of Science ®Google Scholar
• Davey KG, Szekely A, Johnson EM, Warnock DW. Comparison of a new commercial colorimetris microdilution method with a standard method for in-vitro susceptibility testing of Candida spp. and Cryptococcus neoformans. J Antimicrob Chemother 1998; 42: 439–444.
   PubMedGoogle Scholar
• Yamaguchi H, Uchida K, Nagino K, Matsunaga T. Usefulness of a colorimetric method for testing antifungal drug susceptibility of Aspergillus species to voriconazole. J Infect Chemother 2002; 8: 374–377.
   PubMedGoogle Scholar
• Fromting RA, Shadomy HJ, Jacobson ES. Decreased virulence in stable, acapsular mutants of Cryptococcus neoformans. Mycopathologia 1982; 79: 23–29.
   PubMedGoogle Scholar
• Peiris V, Oppenheim BA. Antimicrobial activity of cytotoxic drugs may influence isolation of bacteria and fungi from blood cultures. J Clin Pathol 1993; 46: 1124–1125.
   PubMed Web of Science ®Google Scholar
• Kinnunen U, Syrjälä H, Koistinen P, Koskela M. Idarubicin inhibits the growth of bacteria and yeasts in an automated blood culture system. Eur J Clin Microbiol Infect Dis 2009; 28: 301–303.
   PubMed Web of Science ®Google Scholar
• Borchmann P, Hübel K, Schnell R, Engert A. Idarubicin: a brief overview on pharmacology and clinical use. Int J Clin Pharmacol Ther 1997; 35: 80–83.
   PubMedGoogle Scholar
• Patel K, Craig SB, McBride MG, Palepu NR. Microbial inhibitory properties and stability of topotecan hydrochloride injection. Am J Health Syst Pharm 1998; 55: 1585–1587.
   Google Scholar
• Gilles HC, Herriott D, Liang R, . Pharmacokinetics of idarubicin (4-demethoxydaunorubicin; IMI-30; NSC 256439) following intravenous and oral administration in patients with advanced cancer. Br J Clin Pharmacol 1987; 23: 303–310.
   PubMedGoogle Scholar
• Dos Santos N, Waterhouse D, Masin D, . Substantial increase in idarubicin plasma concentration by liposome encapsulation mediates improved antitumor activity. J Control Release 2005; 105: 89–105.
   PubMed Web of Science ®Google Scholar
• Gubernator J, Chwastek G, Korycińska M, . The encapsulation of idarubicin within liposomes using the novel EDTA ion gradient method ensures improved drug retention in vitro and in vivo. J Control Release 2010; 146: 68–75.
   PubMed Web of Science ®Google Scholar
• Gabizon AA. Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Res 1992; 52: 891–896.
   PubMed Web of Science ®Google Scholar